Logo image of ALCOX.PA

NICOX SA (ALCOX.PA) Stock Fundamental Analysis

EPA:ALCOX - Euronext Paris - Matif - FR0013018124 - Common Stock - Currency: EUR

0.292  +0.01 (+1.74%)

Fundamental Rating

2

Taking everything into account, ALCOX scores 2 out of 10 in our fundamental rating. ALCOX was compared to 72 industry peers in the Biotechnology industry. ALCOX has a bad profitability rating. Also its financial health evaluation is rather negative. ALCOX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALCOX had negative earnings in the past year.
In the past year ALCOX has reported a negative cash flow from operations.
In the past 5 years ALCOX always reported negative net income.
ALCOX had a negative operating cash flow in each of the past 5 years.
ALCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFALCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

ALCOX has a Return On Assets of -21.10%. This is in the better half of the industry: ALCOX outperforms 62.50% of its industry peers.
ALCOX has a Return On Equity (-38.13%) which is in line with its industry peers.
Industry RankSector Rank
ROA -21.1%
ROE -38.13%
ROIC N/A
ROA(3y)-35.8%
ROA(5y)-26.67%
ROE(3y)-69.46%
ROE(5y)-48.73%
ROIC(3y)N/A
ROIC(5y)N/A
ALCOX.PA Yearly ROA, ROE, ROICALCOX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

ALCOX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCOX.PA Yearly Profit, Operating, Gross MarginsALCOX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

ALCOX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALCOX has about the same amount of shares outstanding.
The number of shares outstanding for ALCOX has been increased compared to 5 years ago.
Compared to 1 year ago, ALCOX has a worse debt to assets ratio.
ALCOX.PA Yearly Shares OutstandingALCOX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ALCOX.PA Yearly Total Debt VS Total AssetsALCOX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

ALCOX has an Altman-Z score of -9.58. This is a bad value and indicates that ALCOX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALCOX (-9.58) is worse than 73.61% of its industry peers.
ALCOX has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.40, ALCOX perfoms like the industry average, outperforming 56.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z -9.58
ROIC/WACCN/A
WACC7.42%
ALCOX.PA Yearly LT Debt VS Equity VS FCFALCOX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 2.57 indicates that ALCOX has no problem at all paying its short term obligations.
ALCOX's Current ratio of 2.57 is in line compared to the rest of the industry. ALCOX outperforms 55.56% of its industry peers.
A Quick Ratio of 2.57 indicates that ALCOX has no problem at all paying its short term obligations.
ALCOX has a better Quick ratio (2.57) than 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.57
Quick Ratio 2.57
ALCOX.PA Yearly Current Assets VS Current LiabilitesALCOX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

ALCOX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.16%, which is quite impressive.
The Revenue for ALCOX has decreased by -51.31% in the past year. This is quite bad
ALCOX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.38% yearly.
EPS 1Y (TTM)70.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)-51.31%
Revenue growth 3Y-18.83%
Revenue growth 5Y11.38%
Sales Q2Q%21.19%

3.2 Future

The Earnings Per Share is expected to grow by 13.44% on average over the next years. This is quite good.
Based on estimates for the next years, ALCOX will show a very negative growth in Revenue. The Revenue will decrease by -22.92% on average per year.
EPS Next Y22.2%
EPS Next 2Y13.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year33.68%
Revenue Next 2Y-22.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALCOX.PA Yearly Revenue VS EstimatesALCOX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
ALCOX.PA Yearly EPS VS EstimatesALCOX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALCOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCOX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCOX.PA Price Earnings VS Forward Price EarningsALCOX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCOX.PA Per share dataALCOX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ALCOX's earnings are expected to grow with 13.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALCOX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NICOX SA

EPA:ALCOX (3/7/2025, 7:00:00 PM)

0.292

+0.01 (+1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-23 2025-01-23/amc
Earnings (Next)04-21 2025-04-21
Inst Owners6.35%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap20.24M
Analysts84.44
Price Target1.02 (249.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.66
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.05
BVpS0.66
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.1%
ROE -38.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.8%
ROA(5y)-26.67%
ROE(3y)-69.46%
ROE(5y)-48.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.74%
Cap/Sales 2.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.57
Quick Ratio 2.57
Altman-Z -9.58
F-Score2
WACC7.42%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y22.2%
EPS Next 2Y13.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-51.31%
Revenue growth 3Y-18.83%
Revenue growth 5Y11.38%
Sales Q2Q%21.19%
Revenue Next Year33.68%
Revenue Next 2Y-22.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.36%
OCF growth 3YN/A
OCF growth 5YN/A